Edgewise Therapeutics, Inc. (EWTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$39.31-1.70%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Edgewise Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	9.62M
EPS	—	-0.483
Annual ending 2026-12-31
Revenue	—	2.27M
EPS	—	-2.054
Annual ending 2027-12-31
Revenue	—	35.43M
EPS	—	-1.64

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Report CIRRUS-HCM Part D 12-week data by end of Q2 2026	Edgewise Therapeutics is advancing its CIRRUS-HCM Part D data reporting on time by Q2 2026.	Intact	Data report delayed beyond Q2 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management reported positive 12-week CIRRUS-HCM Part D data in Q2 2026, which is expected to inform Phase 3 trial initiation in Q4 2026. This milestone was delivered on schedule, matching management's stated timeline. Delivery assessment Oct 24, 2026
EPS remains positive in 2026 with improvement from prior losses	Earnings have shown improvement with recent beats.	Broken	EPS falls below 1.28 USD in FY 2026	Diluted EPS: $-0.53 per share FY2026-Q2; GAAP. Published target: EPS >= 1.28 USD in FY 2026. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.53 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: fcf00dbb-75d2-476e-ad40-b69edb0df35e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful integration and execution of asset purchase agreement with Servier Pharmaceuticals	The company recently made a positive asset purchase agreement with Servier Pharmaceuticals.	Intact	Failure to execute or integrate asset purchase by end 2026	Asset purchase completed 2026-07-10 vs end-2026 target Form 8-K confirms completion of the acquisition of sevasemten and related assets by Servier on July 10, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.64

$-1.66 → $-1.64 · observed estimates

FY2027 revenue$0.04B

$0.04B → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.66	$40,709,091	7 / 6
2026-07-25	$-1.47	$52,500,000	8 / 8
2026-07-26	$-1.47	$52,500,000	8 / 8
2026-07-27	$-1.47	$52,500,000	8 / 8
2026-07-28	$-1.66	$40,709,091	7 / 6
2026-07-29	$-1.47	$52,500,000	8 / 8
2026-07-30	$-1.66	$40,709,091	7 / 6
2026-07-31	$-1.47	$52,500,000	8 / 8
2026-08-01	$-1.66	$40,709,091	7 / 6
2026-08-02	$-1.47	$52,500,000	8 / 8
2026-08-03	$-1.47	$52,500,000	8 / 8
2026-08-04	$-1.66	$40,709,091	7 / 6
2026-08-05	$-1.47	$52,500,000	8 / 8
2026-08-06	$-1.47	$52,500,000	8 / 8
2026-08-07	$-1.73	$40,709,091	7 / 6
2026-08-08	$-1.47	$52,500,000	8 / 8
2026-08-09	$-1.47	$52,500,000	8 / 8
2026-08-10	$-1.73	$40,709,091	7 / 6
2026-08-11	$-1.73	$40,709,091	7 / 6
2026-08-12	$-1.72	$47,000,000	10 / 10
2026-08-13	$-1.73	$40,709,091	7 / 6
2026-08-14	$-1.73	$40,709,091	7 / 6
2026-08-15	$-1.73	$40,709,091	8 / 7
2026-08-16	$-1.73	$40,709,091	8 / 7
2026-08-17	$-1.73	$40,709,091	8 / 7
2026-08-18	$-1.73	$40,709,091	8 / 7
2026-08-19	$-1.73	$40,709,091	8 / 7
2026-08-20	$-1.61	$38,645,455	9 / 8
2026-08-21	$-1.64	$38,645,455	9 / 8
2026-08-22	$-1.64	$38,645,455	9 / 8
2026-08-23	$-1.64	$38,645,455	9 / 8
2026-08-24	$-1.64	$38,645,455	9 / 8
2026-08-25	$-1.64	$38,645,455	9 / 8
2026-08-26	$-1.64	$38,645,455	9 / 8
2026-08-27	$-1.64	$38,645,455	9 / 8
2026-08-28	$-1.64	$38,645,455	9 / 8
2026-08-29	$-1.64	$38,645,455	9 / 8
2026-08-30	$-1.64	$38,645,455	9 / 8
2026-08-31	$-1.64	$38,645,455	9 / 8
2026-09-01	$-1.64	$38,645,455	9 / 8
2026-09-02	$-1.64	$38,645,455	9 / 8
2026-09-03	$-1.64	$38,645,455	9 / 8
2026-09-04	$-1.64	$38,645,455	9 / 8
2026-09-05	$-1.64	$38,645,455	9 / 8
2026-09-06	$-1.64	$38,645,455	9 / 8
2026-09-07	$-1.64	$38,645,455	9 / 8
2026-09-08	$-1.64	$38,645,455	9 / 8
2026-09-09	$-1.64	$38,645,455	9 / 8
2026-09-10	$-1.64	$38,645,455	9 / 8
2026-09-11	$-1.64	$38,645,455	9 / 8
2026-09-12	$-1.64	$38,645,455	9 / 8
2026-09-13	$-1.64	$38,645,455	9 / 8
2026-09-14	$-1.64	$38,645,455	9 / 8
2026-09-15	$-1.64	$38,645,455	9 / 8
2026-09-16	$-1.64	$38,645,455	9 / 8
2026-09-17	$-1.64	$38,645,455	9 / 8
2026-09-18	$-1.64	$38,645,455	9 / 8
2026-09-19	$-1.64	$38,645,455	9 / 8
2026-09-20	$-1.64	$38,645,455	9 / 8
2026-09-21	$-1.64	$38,645,455	9 / 8
2026-09-22	$-1.64	$38,645,455	9 / 8
2026-09-23	$-1.64	$38,645,455	9 / 8
2026-09-24	$-1.64	$38,645,455	9 / 8
2026-09-25	$-1.64	$38,645,455	9 / 8
2026-09-26	$-1.64	$38,645,455	9 / 8
2026-09-27	$-1.64	$38,645,455	9 / 8
2026-09-28	$-1.64	$38,645,455	9 / 8
2026-09-29	$-1.64	$38,645,455	9 / 8
2026-09-30	$-1.64	$38,645,455	9 / 8
2026-10-01	$-1.64	$38,645,455	9 / 8
2026-10-02	$-1.64	$38,645,455	9 / 8
2026-10-03	$-1.64	$38,645,455	9 / 8
2026-10-04	$-1.64	$38,645,455	9 / 8
2026-10-05	$-1.64	$38,645,455	9 / 8
2026-10-06	$-1.64	$38,645,455	9 / 8
2026-10-07	$-1.64	$38,645,455	9 / 8
2026-10-08	$-1.64	$38,645,455	9 / 8
2026-10-09	$-1.64	$38,645,455	9 / 8
2026-10-10	$-1.64	$38,645,455	9 / 8
2026-10-11	$-1.64	$38,645,455	9 / 8
2026-10-12	$-1.64	$38,645,455	9 / 8
2026-10-13	$-1.64	$38,645,455	9 / 8
2026-10-14	$-1.64	$38,645,455	9 / 8
2026-10-15	$-1.64	$38,645,455	9 / 8
2026-10-16	$-1.64	$38,645,455	9 / 8
2026-10-17	$-1.64	$38,645,455	9 / 8
2026-10-18	$-1.64	$35,425,000	10 / 8
2026-10-19	$-1.64	$35,425,000	10 / 9
2026-10-20	$-1.64	$35,425,000	10 / 9
2026-10-21	$-1.64	$35,425,000	10 / 9
2026-10-22	$-1.64	$35,425,000	10 / 9
2026-10-23	$-1.64	$35,425,000	10 / 9
2026-10-24	$-1.64	$35,425,000	10 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	2
2026-06-01	10	2
2026-07-01	11	2
2026-08-01	11	2
2026-09-01	11	2
2026-10-01	12	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Report CIRRUS-HCM Part D 12-week data by end of Q2 2026Qualitative condition
EPS remains positive in 2026 with improvement from prior lossesPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-25.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Edgewise Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology story, not an established earnings compounder. The thesis is on watch: management has delivered key milestones, but recent financial performance is weak and the evidence snapshot carries low overall confidence.

What's priced into Edgewise Therapeutics, Inc.

The snapshot provides no valuation measure or clear account of market expectations, so whether EWTX is cheap or expensive versus peers cannot be assessed. It reports no valuation fragility flags, but that does not establish what expectations are already reflected.

What the fundamentals likely do

Near term, the company remains loss-making, and the latest recorded earnings event was a miss. Management has advanced its stated priorities, including positive 12-week CIRRUS-HCM data and plans for later-stage trials; the sale of its muscular dystrophy business also lifted pro forma cash to over $2 billion. Near-term results remain uncertain, with elevated risk and a 44% estimated miss probability in the snapshot.

What Edgewise Therapeutics, Inc. hinges on

The multi-year view depends on advancing EDG-7500 and EDG-15400 through planned clinical trials and on whether the cardiovascular pipeline produces further supportive evidence. A guidance cut would be a negative signal, while stronger results and guidance from sector peers could support the healthcare backdrop. Weakening jobs data may add pressure through recession concerns, though this is a broader sector risk rather than company-specific proof.